The Patient-Reported Outcomes, Survey, and Population Research (PROSPR) shared resource is a centralized source of expertise in the science of collecting and managing participant-reported outcome (PRO) and behavioral data. These data are important in many treatment trials (e.g., to evaluate the impact of treatment on quality of life and symptoms), survivorship studies, and in cancer prevention research. The PROSPR offers services in 3 areas: research support services, which have seen a 100% increase in utilization over the past 5 years, data support services (12% increase), and fitness and body composition testing (new service in 2011). PROSPR has access to a SQL server, as well as equipment for testing fitness and body composition (Hologic bone densitometer, Biodex for measuring strength, 3 metabolic carts, 3 ECGs, 2 cycle ergometers, 1 treadmill, a perometer, and a bank of 150 actigraphs). In the past 5 years, the PROSPR facility has served 112 investigators in 17 programs. PROSPR has facilitated 47 publications with articles appearing in JAMA and J Clin Oncol. Center members with peer-reviewed funding account for 80% of users, and 32% of total costs are requested from the CCSG. The institution has provided $431,072 in financial support for the shared resource since 2008 for operational costs and for equipment, including an HP server, 3 Dell precision workstations, and 150GT3XE-plus triaxial activity monitors. In addition, the fitness and body composition equipment was purchased by the institution. Over the next 5 years, PROSPR will improve its expertise and expand services in design and data management for computer-assisted data collection (e.g., ecological momentary assessment, computer adaptive testing, and internet-based surveys) and expand its expertise in body composition testing.

Public Health Relevance

PROSPR provides assistance to MD Anderson investigators with collection and assessment of Patient Reported Outcomes, behavioral data, and measures of fitness and body composition. These data are central to cancer prevention and survivorship research, and are increasingly incorporated being into cancer treatment trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Daver, Naval; Verstovsek, Srdan (2015) Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. Leuk Lymphoma 56:279-80
Burstein, Matthew D; Tsimelzon, Anna; Poage, Graham M et al. (2015) Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 21:1688-98
Mersch, Jacqueline; Jackson, Michelle A; Park, Minjeong et al. (2015) Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121:269-75
Pugh, Thomas J; Mahmood, Usama; Swanson, David A et al. (2015) Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. Brachytherapy 14:160-5
Zuo, Zhuang; Maiti, Sourindra; Hu, Shimin et al. (2015) Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol 28:373-82
Martin, Neil E; Massey, Laura; Stowell, Caleb et al. (2015) Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol 67:460-7
Shen, Qi; Ouyang, Juan; Tang, Guilin et al. (2015) Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol 95:168-76
Massarweh, Nader N; Haynes, Alex B; Chiang, Yi-Ju et al. (2015) Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough? Ann Surg 262:312-20
Garcia-Manero, Guillermo; Khoury, Hanna J; Jabbour, Elias et al. (2015) A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res 21:985-94
Brown, Alaina J; Sun, Charlotte C; Urbauer, Diana et al. (2015) Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer 23:2025-32

Showing the most recent 10 out of 2114 publications